May 13th 2024
While urologists and oncologists agreed on many barriers and facilitators of first-line treatment intensification for metastatic castrate-sensitive prostate cancer, there were also a number of differing beliefs, including whether there is enough clinical support.
Characterizing Medical Care by Disease Phase in Metastatic Colorectal Cancer
This study characterized patterns and costs of medical care by disease phase in patients with newly diagnosed mCRC using a large US national commercially insured claims database.
Read More
Advancing Performance Measurement in Oncology
The American Society of Clinical Oncology Quality Oncology Practice Initiative has grown to include 973 practices as of 2010. Practices demonstrated rates of end-of-life care and other measures of quality.
Read More
Patient and Plan Characteristics Affecting Abandonment of Oral Oncolytic Prescriptions
May 20th 2011Ten percent of patients abandon newly initiated oral oncolytics at the pharmacy. Patients facing higher cost sharing or increased concurrent prescription activity have a higher abandonment rate.
Read More
Pathways, Outcomes, and Costs in Colon Cancer: Retrospective Evaluations in 2 Distinct Databases
Retrospective evaluations of electronic health records and claims databases to assess clinical outcomes and costs associated with evidence-based pathways in colon cancer.
Read More
Racial Variation in the Cost-effectiveness of Chemotherapy for Prostate Cancer
May 18th 2011The likelihood of chemotherapy being cost-effective for patients with metastatic prostate cancer differs across racial subgroups. This uncertainty presents challenges for managed-care decision makers.
Read More
Do Economic Evaluations of Targeted Therapy Provide Support for Decision Makers?
May 17th 2011Economic evaluations of adjuvant trastuzumab were reviewed. Three primary shortcomings were identified including incorporation of local data and estimation and representation (visual) of decision uncertainty.
Read More
Impact of New Drugs and Biologics on Colorectal Cancer Treatment and Costs
We measured the financial consequences of new CRC treatment regimens. New regimens have increased cost directly through price and indirectly through nonstandard and second-line regimen use.
Read More
Impact of Clinical Oral Chemotherapy Program on Wastage and Hospitalizations
An oral chemotherapy cycle management program offers clinical support, reduces medication wastage, and provides management of adverse effects to realize cost savings for payers and patients.
Read More
Genomic Testing and Therapies for Breast Cancer in Clinical Practice
Despite almost universal testing for human-epidermal-growth-factor-receptor-2 (HER2), many women with a HER2-positive cancer may not receive trastuzumab. Fewer women received the newer gene-expression-profile (GEP) test.
Read More
Journey Forward: The New Face of Cancer Survivorship Care
May 13th 2011WellPoint, UCLA's Jonsson Comprehensive Cancer Center, the National Coalition for Cancer Survivorship (NCCS) and Genentech collaborated to develop Journey Forward, a first-of-its-kind program for coordinating post-treatment care.
Read More
Primary Care and Communication in Shared Cancer Care: A Qualitative Study
This qualitative study assesses patient, PCP, and oncologist views on primary care roles in shared cancer care, as well as patterns of communication between physicians.
Read More